Published in Vaccine Weekly, September 13th, 2000
"The objective of this trial was to determine the feasibility of combining infusional CDE with rituximab," stated Umberto Tirelli and colleagues from the Center Riferimento Oncologico, Italy, and the Albert Einstein Comprehensive Cancer Center, New York. "The rationale for adding rituximab include its activity in refractory lymphoma, its non-overlapping toxicity and differing mechanism of action."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.